ALT

Insider Trades

Name	Value	Action	Price	Current Price
Gill JohnDirector $31k9.2k shares BuyApr 6, 2026 $3.41 --
Durso Jerome BenedictDirector, Officer: President And CEO $47k15k shares BuyApr 1, 2026 $3.14 --
Weaver Gregory LChief Financial Officer $31k10k shares BuyApr 1, 2026 $3.15 --
Durso Jerome BenedictDirector, Officer: President And CEO $71k20k shares BuyMar 6, 2026 $3.54 --
Weaver Gregory LChief Financial Officer $18k5k shares BuyMar 6, 2026 $3.54 --
Pisano WayneDirector $20k5k shares BuyJan 8, 2026 $4.08 --

News

zacks.comWhy Is Altimmune (ALT) Down 11.3% Since Last Earnings Report?zacks.comJun 12

seekingalpha.comAltimmune, Inc. (ALT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.comJun 10

marketbeat.comAltimmune Sets Pemvidutide's Phase 3 MASH Playbook as AUD Data Nearmarketbeat.comJun 10

zacks.comALT Stock Guide to Pemvidutide's MASH, AUD and ALD Setupzacks.comJun 8

zacks.comALT and the Rise of Dual Agonists Targeting Liver Diseasezacks.comJun 8

Trade ALT

About Altimmune, Inc.

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.

CEO: Jerome Benedict Durso
IPO Date: May 26, 2017

Market Data

Open: $2.69
High: $2.77
Low: $2.68
Volume: 9M
Avg Volume: 3.8M
52W High: $7.73
52W Low: $2.56

Valuation

Market Cap: $238M
Enterprise Value: $177M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-68M
Revenue: $41k
Net Income: $-88M
Cash: $44M
Debt: $36M

Events

EarningsAug 11

EPS est. -0.17